Vol 13, No 4 (August 15, 2024): Chinese Clinical Oncology

Editorial

Artificial intelligence for personalized therapy
Yasuhide Yamada
Chinese Clinical Oncology  
2024;
13
(4)
:47
.

Review Article

Interleukine-10 in ovarian cancer
Gabriel Levin, Walter Henry Gotlieb
Chinese Clinical Oncology  
2024;
13
(4)
:48
.
Challenges and solutions in 3D printing for oncology: a narrative review
Mateusz Jacek Spałek, Aleksandra Bochyńska, Aneta Borkowska, Paweł Mroczkowski, Bartłomiej Szostakowski
Chinese Clinical Oncology  
2024;
13
(4)
:49
.
Functional outcomes of bony sarcoma (BS) in Adolescent and Young Adult Oncology (AYAO) patients—a scoping review
Zheng Xuan Ong, Eileen Poon
Chinese Clinical Oncology  
2024;
13
(4)
:50
.
A critical appraisal of the current landscape of resectable BRAF mutated colorectal liver metastases: a systematic review
Georgios Antonios Margonis, Jaeyun Wang, Dimitris Papakonstantinou, Katharina Beyer, Martin E. Kreis, Michael D’Angelica
Chinese Clinical Oncology  
2024;
13
(4)
:51
.
Current applications of ex-vivo fluorescent confocal microscope in urological practice: a systematic review of literature
Ahmed Eissa, Stefano Puliatti, Natali Rodriguez Peñaranda, Stefano Resca, Stefano Di Bari, Jessica Vella, Sofia Maggiorelli, Laura Bertoni, Paola Azzoni, Luca Reggiani Bonetti, Davide Campobasso, Stefania Ferretti, Salvatore Micali, Giampaolo Bianchi
Chinese Clinical Oncology  
2024;
13
(4)
:52
.
Unusual metastases to the breast from different extramammary malignancies: a multimodality imaging approach in a case series
Liliana Moreno-Astudillo, Karla Abundiz, Yolanda Villaseñor-Navarro, Laura Vidal Olivares, Fany Porras Reyes, Isabel Sollozo-Dupont
Chinese Clinical Oncology  
2024;
13
(4)
:53
.
Advancements in artificial intelligence for robotic-assisted radical prostatectomy in men suffering from prostate cancer: results from a scoping review
Daniele Castellani, Leonard Perpepaj, Demetra Fuligni, Giuseppe Chiacchio, Pietro Tramanzoli, Silvia Stramucci, Virgilio De Stefano, Vanessa Cammarata, Simone Cappucelli, Valerio Pasarella, Stefania Ferretti, Davide Campobasso, Vineet Gauhar, Andrea Benedetto Galosi
Chinese Clinical Oncology  
2024;
13
(4)
:54
.
From simulation to surgery, advancements and challenges in robotic training for radical prostatectomy: a narrative review
Marco Ticonosco, Alessandro Pissavini, Claudia Collà Ruvolo, Nicola Frego, Mario Belmonte, Francesco Barletta, Simone Morra, Silvia Rebuffo, Gabriele Sorce, Florencio Marin, Davide Campobasso, Anthony G. Gallagher, Stefania Ferretti, Lorenzo Bianchi, Riccardo Schiavina, Stefano Puliatti, Salvatore Micali, Alexandre Mottrie
Chinese Clinical Oncology  
2024;
13
(4)
:55
.
3D virtual models and augmented reality for radical prostatectomy: a narrative review
Marcello Della Corte, Alberto Quarà, Sabrina De Cillis, Gabriele Volpi, Daniele Amparore, Federico Piramide, Alberto Piana, Michele Sica, Michele Di Dio, Stefano Alba, Francesco Porpiglia, Enrico Checcucci, Cristian Fiori
Chinese Clinical Oncology  
2024;
13
(4)
:56
.

Editorial Commentary

Dual PD-1/PD-L1 and CTLA-4 inhibition strategies: tailoring immunotherapy for metastatic non-small cell lung cancer
Takayuki Kobayashi, Taiki Hakozaki
Chinese Clinical Oncology  
2024;
13
(4)
:58
.
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma—a commentary on KEYNOTE-811
James Yu, Anwaar Saeed
Chinese Clinical Oncology  
2024;
13
(4)
:59
.
Zolbetuximab on the SPOTLIGHT—a light spot?
Renata D’Alpino Peixoto, Mauro Daniel Spina Donadio
Chinese Clinical Oncology  
2024;
13
(4)
:60
.
The landscape of perioperative immunotherapy in non-small cell lung cancer: what have we learned from the AEGEAN trial?
Jingxiao Jin, Timothy F. Burns
Chinese Clinical Oncology  
2024;
13
(4)
:61
.
ESO-Shanghai 13: another milestone in the treatment of oligometastatic disease?
Alexander Grabenbauer, Tiuri E. Kroese, Matthias Guckenberger
Chinese Clinical Oncology  
2024;
13
(4)
:62
.

Letter to the Editor

Accelerated aging and young-onset cancer risk!—are stressors of the PELICan hypothesis the missing link?
Savio George Barreto, Stephen J. Pandol
Chinese Clinical Oncology  
2024;
13
(4)
:63
.

Original Article

Efficacy and safety of PARP inhibitors in the treatment of prostatic cancer: a systematic review and network meta-analysis
Yueting Huang, Hui He, Lufan Liang, Yuxiang Zhang, Kaoqing Peng, Yubo Wang, Jianhao Wu, Xuezhi Long, Kalevi Kairemo, Hanan Goldberg, Lucas C. Mendez, Di Gu
Chinese Clinical Oncology  
2024;
13
(4)
:64
.